Intravenous Oxytocin Versus Tranexamic Acid in Reducing Blood Loss During Abdominal Myomectomy.

PHASE4CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

April 30, 2019

Primary Completion Date

February 1, 2020

Study Completion Date

March 15, 2020

Conditions
Myomectomy
Interventions
DRUG

Tranexamic Acid

Patients in the TXA group will be given 15 mg/kg of tranexamic acid (Cyklokapron@; Amoun Pharmaceutical Co., SAE) slowly intravenously 30 min before surgery followed by 10 mg/ kg/h infusion in 500 ml Ringer's by infusion pump till the end of the procedure.

DRUG

oxytocin

An equal volume of normal saline syringe in a double blinded manner will be intravenously administered to the OXYtocin group 30 min before surgery and will be followed by one ampoule of oxytocin (10 U/mL/amp) (Syntocinon; Aventis Pharmaceutical Co.) will be added to 500 mL Ringer's solution running at a rate of 400 mU/min by infusion pump till the end of the procedure.

DRUG

placebo

An equal volume of normal saline syringe in a double blinded manner will be intravenously administered to the Oxytocin group 30 min before surgery and will be followed by 500 ml saline infusion during the operation

Trial Locations (1)

11231

faculty of medicine Cairo university, Giza

All Listed Sponsors
lead

Cairo University

OTHER

NCT03892668 - Intravenous Oxytocin Versus Tranexamic Acid in Reducing Blood Loss During Abdominal Myomectomy. | Biotech Hunter | Biotech Hunter